These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 16020960

  • 1. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
    Cho EK, Lee WK, Im SA, Lee SN, Park SH, Bang SM, Park DK, Park YH, Shin DB, Lee JH.
    Oncology; 2005; 68(4-6):333-40. PubMed ID: 16020960
    [Abstract] [Full Text] [Related]

  • 2. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
    Ocvirk J, Reberšek M, Skof E, Hlebanja Z, Boc M.
    Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
    [Abstract] [Full Text] [Related]

  • 3. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E.
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Evans TR, Pentheroudakis G, Paul J, McInnes A, Blackie R, Raby N, Morrison R, Fullarton GM, Soukop M, McDonald AC.
    Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
    Woo IS, Moon DH, Shim BY, Lee MA, Byun JH, Kim KW, Kang JH, Choi MG, Chung IS, Hong YS, Park SY, Lee KS.
    Jpn J Clin Oncol; 2005 Jan; 35(1):13-7. PubMed ID: 15681598
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
    Salah-Eldin MA, Ebrahim MA, AL-Ashry MS.
    Anticancer Drugs; 2009 Mar; 20(3):191-6. PubMed ID: 19396018
    [Abstract] [Full Text] [Related]

  • 10. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK.
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
    Lim JY, Cho JY, Paik YH, Lee DK, Lee SI, Park HJ, Lee SJ, Lee KS, Yoon DS, Choi SH.
    Oncology; 2007 Jan; 73(1-2):2-8. PubMed ID: 18332648
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
    Kang YK, Ryu MH, Yoo C, Chang HM, Yook JH, Oh ST, Kim BS, Kim TW.
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1435-43. PubMed ID: 20811894
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK.
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT, Yoon SY, Shin SW, Kim BS, Mok YJ, Kim CS, Hyun JH, Kim JS, Kim YH.
    Cancer; 2001 Jun 15; 91(12):2288-93. PubMed ID: 11413517
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
    Idelevich E, Karminsky N, Dinerman M, Katsenelson RL, Zvi NB, Baruch NB, Biran H, Man S, Shani A.
    Acta Oncol; 2007 Jun 15; 46(3):324-9. PubMed ID: 17450467
    [Abstract] [Full Text] [Related]

  • 19. [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
    Hu B, Yu JR, Wen ZZ, Shu YQ, Wang BC, Yin HR, Chen L, Bai YX, Liang J, Chen L, Cheng Y, Shen L, Zhou Y, Zhang HG, Li J, Wan DS, Chen S, Jia TZ, Jin ML.
    Zhonghua Zhong Liu Za Zhi; 2008 Dec 15; 30(12):940-3. PubMed ID: 19173999
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
    Baize N, Abakar-Mahamat A, Mounier N, Berthier F, Caroli-Bosc FX.
    Cancer Chemother Pharmacol; 2009 Aug 15; 64(3):549-55. PubMed ID: 19123051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.